A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients

NCT03419975 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open-angle Glaucoma
Ocular Hypertension

Interventions

DRUG: TJO-002
DRUG: Latanoprost

Sponsor

Taejoon Pharmaceutical Co., Ltd.